27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

Slides:

Advertisements

Similar presentations

Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.

Advertisements

An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.

1 Goals of a Lotronex ® Risk Management Program Toni Piazza-Hepp, Pharm.D. Deputy Director Division of Surveillance, Research and Communication Support.

10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.

FDA REGULATION: EFFECT ON PAIN MANAGEMENT IN THE ED RICHARD R. ABOOD, R.Ph., J.D. Professor Pharmacy Practice University of the Pacific RICHARD R. ABOOD,

Medication Guides Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications.

REMS Update NORD Corporate Council Meeting May 14, 2013

Presented at the 2008 International Symposium on Pharmaceuticals in the Home and Environment: Catalysts for Change, November 10-11, 2008 and to be used.

Drug Utilization Review (DUR)

Capturing and Reporting Adverse Events in Clinical Research

RAC Study Group Chapter 16

Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.

FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.

1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.

FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’

April 8, 2005FDLI Annual Conference 1 Labeling Prescription Drugs for Physicians and Consumers (FDA Perspective) Paul J. Seligman, MD, MPH Director, Office.

Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.

Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP.

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?

1 FDA DRAFT GUIDANCE FOR INDUSTRY REVISED Stuart E Coleman Promotional Review and Regulatory March 30 th, 2015.

MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.

Responsibilities and Principles of Drug Administration

Opioid Risk Management Programs Celia Jaffe Winchell, M.D. Acting Deputy Division Director Division of Anesthetic, Critical Care, and Addiction Drug Products.

ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.

Planned Emergency Research Exception from Informed Consent Requirements September 2007.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Evolution of Risk Management for Systemic Retinoids Evolution of Risk Management for.

FDA Risk Management Workshop: Concept Paper: Risk Management Programs April 10, 2003 Gary C. Stein, Ph.D. Director of Federal Regulatory Affairs American.

Communication of Drug Safety Information Food and Drug Administration Center for Drug Evaluation & Research Public Hearing December 8, 2005.

1 PhRMA Guiding Principles - DTC About Prescription Medicines.

Sidney M. Wolfe M.D and Sherri Shubin M.D., M.P.H. Public Citizen’s Health Research Group FDA Drug Safety and Risk Management and Dermatologic and Ophthalmic.

FDA Regulation of Prescription Drug Promotion Thomas W. Abrams, R.Ph., MBA Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.

Medication Error Reduction Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.

History of Pediatric Labeling

Prof. Moustafa M. Mohamed Vice dean Dr. Safa Ahmed El-askary Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation.

Praxbind® - Idarucizumab

Investigational Devices and Humanitarian Use Devices June 2007.

The Dilemma of Diclofenac Injection for the Iranian Health System Authors: Shalviri G, Cheraghali M, Gholami K, Kamali E, Daryabari N Institution: Ministry.

Focus on Nursing Pharmacology

July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.

Signal identification and development I.Ralph Edwards.

Pharmaceutical post operational activities

FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,

RESTICTED DRUGS Risk Evaluation and Mitigation Strategies--REMS

1 Presentation of the Pharmaceutical Research and Manufacturers of America at FDA Part 15 Hearing on Communication of Drug Safety Information December.

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.

27 June 2000Victor F. C. Raczkowski, M.D.1 Benefit-Risk Reevaluation of Marketed Drugs Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory.

Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.

Nonprescription Drugs Advisory Committee Meeting Charles J. Ganley, M.D. Division of OTC Drug Products September 19, 2002.

Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.

Pharmacy Agencies Drug Development and Control Health Science Pharmacy Technician Virginia Parker.

Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.

Patient Safety and Quality: Where Does Health Care in Schools Fit In? Howard Bauchner, M.D. Professor of Pediatrics & Public Health Director, Division.

Developing, Pilot Testing & Evaluating RiskMAP Interventions Annette Stemhagen, DrPH, FISPE Vice President UBC Epidemiology & Risk Management The FDA Regulatory.

Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.

Prescription Drug Advertising

8. Causality assessment:

3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.

9. Introduction to signal detection

Black Box Warning What You Need To Know.

AndroGel Package Label Changes

Presentation transcript:

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June 2000

Victor F. C. Raczkowski, M.D.2 Risk-Management Options for Marketed Drugs Labeling Communications and Educational Programs Advertising Packaging Restricted Distribution Withdrawal

27 June 2000Victor F. C. Raczkowski, M.D.3 Labeling Components Labels –Immediate container –Outer package Package insert for prescription drugs –Professional labeling –Patient Package Insert Medication Guides

27 June 2000Victor F. C. Raczkowski, M.D.4 Patient Package Inserts (PPI) Extension of professional labeling Can be distributed to patients when drug dispensed Important information about the drug in lay language Lotronex currently has a PPI

27 June 2000Victor F. C. Raczkowski, M.D.5 Medication Guides for Prescription Drugs Information leaflet for patients FDA can require one: 21 CFR 208 Must be distributed to patients when drug dispensed May be used with unit-of-use packaging to enforce its distribution

27 June 2000Victor F. C. Raczkowski, M.D.6 Lotronex Labeling: Anticipated Principal Changes Indications and Usage Contraindications Warnings Precautions Adverse Events Patient Package Insert

27 June 2000Victor F. C. Raczkowski, M.D.7 Warnings Describes serious adverse reactions and potential safety hazards Describes limitations in use imposed by serious adverse reactions Describes steps that should be taken if serious adverse reactions occur

27 June 2000Victor F. C. Raczkowski, M.D.8 Warnings Reasonable evidence of an association of a serious hazard with drug Causal relationship need not have been proved

27 June 2000Victor F. C. Raczkowski, M.D.9 Boxed Warnings Special problems, particularly those that may lead to death or serious injury Increases prominence of warning Can be required by FDA Ordinarily based on clinical data

27 June 2000Victor F. C. Raczkowski, M.D.10 Boxed Warnings May be based on serious animal toxicity Specify frequency of serious adverse reactions and, if known, approximate mortality and morbidity rates from reaction Advertising consequence: No reminder ads

27 June 2000Victor F. C. Raczkowski, M.D.11 Boxed Warnings: How Used? Adverse reaction serious in proportion to potential benefit Benefit-risk should be considered before drug is prescribed

27 June 2000Victor F. C. Raczkowski, M.D.12 Boxed Warnings: How Used? Serious adverse reaction, preventable or decreased in frequency or severity by: –Appropriate patient selection –Careful monitoring (e.g., LFTs for hepatotoxicity) –Avoiding certain concomitant therapy –Avoiding use in specific clinical situation

27 June 2000Victor F. C. Raczkowski, M.D.13 Boxed Warnings: How Used? Contraindicated situations Important risk/benefit information about a drug (e.g., drug is the only one in class to have a particular risk that makes it inappropriate for first-line therapy)

27 June 2000Victor F. C. Raczkowski, M.D.14 Boxed Warning for Lotronex? Constipation: –Clear causal relationship with Lotronex –Constipation reported as serious adverse event in 7 patients taking Lotronex 6 patients hospitalized 3 patients underwent surgery

27 June 2000Victor F. C. Raczkowski, M.D.15 Boxed Warning for Lotronex? Ischemic colitis: –Causal relationship to Lotronex suggested in clinical trials and confirmed after marketing –Ischemic colitis reported as serious adverse event in 12 patients taking Lotronex 8 patients hospitalized Remaining 4 patients required endoscopy –Lack of serious sequelae (e.g., colectomy, death) reassuring?

27 June 2000Victor F. C. Raczkowski, M.D.16 Communications and Educational Programs Communications to health care practitioners and consumers –Dear Healthcare Practitioner letter & mailing by the sponsor –Press Releases and Talk Papers for the Press and posting in the FDA Website –Health Advisories to communicate serious health risks

27 June 2000Victor F. C. Raczkowski, M.D.17 Communications and Educational Programs Communications to health care practitioners and consumers –Educational Programs by sponsors directed to healthcare practitioners to ensure optimal prescribing and implementation of necessary precautions

27 June 2000Victor F. C. Raczkowski, M.D.18 Communications and Educational Programs –Educational Programs by sponsors for the public/patients through toll free numbers, internet sites, newsletters, and collaborative efforts with patient advocacy groups –Sales force outreach

27 June 2000Victor F. C. Raczkowski, M.D.19 Advertising –Voluntary restriction to journal type –Voluntary restriction of direct to consumer ads –Ads must present a brief, accurate and balanced representation of adverse reactions, contraindications, and effectiveness –Reminder ads that call attention to the name of the drug only are not permitted for drugs with a Boxed Warning

27 June 2000Victor F. C. Raczkowski, M.D.20 Packaging and Restricted Distribution Packaging - Unit of Dose packaging used with patient package insert/med guide Restricted Distribution - Mechanism to ensure safer use and availability of drug of benefit over existing treatments to treat serious or life threatening conditions Restricted Distribution may be voluntary

27 June 2000Victor F. C. Raczkowski, M.D.21 Withdrawal Cessation of Marketing –Voluntary Withdrawal by the sponsor –Withdrawal of Approval/Imminent Hazard

27 June 2000Victor F. C. Raczkowski, M.D.22 Conclusion Many options are available to help manage risk for Lotronex interventions would be considered.

27 June 2000Victor F. C. Raczkowski, M.D.23 Discussion Points Discuss which risk-management tools should be used for Lotronex Specify next steps if goals of a risk- management program for Lotronex are not being realized Discuss when additional risk-management tools should be implemented (e.g., thresholds)